

2019 Future of Attention Deficit Hyperactivity Disorder (ADHD) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/237EE48940EEN.html>

Date: February 2019

Pages: 140

Price: US\$ 2,199.00 (Single User License)

ID: 237EE48940EEN

Abstracts

The global demand for Attention Deficit Hyperactivity Disorder (ADHD) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Attention Deficit Hyperactivity Disorder (ADHD) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline companies from advancing their products into Phase 3 or Phase 4.

Attention Deficit Hyperactivity Disorder (ADHD) Report Description-

The 2019 pipeline study on Attention Deficit Hyperactivity Disorder (ADHD) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Attention Deficit Hyperactivity Disorder (ADHD) pipeline compounds.

The Attention Deficit Hyperactivity Disorder (ADHD) pipeline guide presents information on all active drugs currently being developed for Attention Deficit Hyperactivity Disorder (ADHD). The research work provides details of active therapeutic candidates in different

phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Attention Deficit Hyperactivity Disorder (ADHD) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Attention Deficit Hyperactivity Disorder (ADHD) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Attention Deficit Hyperactivity Disorder (ADHD) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Attention Deficit Hyperactivity Disorder (ADHD) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Attention Deficit Hyperactivity Disorder (ADHD) pipeline report includes-

An overview of Attention Deficit Hyperactivity Disorder (ADHD) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Attention Deficit Hyperactivity Disorder (ADHD) pipeline

Company wise list of Attention Deficit Hyperactivity Disorder (ADHD) pipeline

Mechanism of Action wise Attention Deficit Hyperactivity Disorder (ADHD) pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Attention Deficit Hyperactivity Disorder (ADHD) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Attention Deficit Hyperactivity Disorder (ADHD) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Attention Deficit Hyperactivity Disorder (ADHD) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Attention Deficit Hyperactivity Disorder (ADHD) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Attention Deficit Hyperactivity Disorder (ADHD) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Candidates

4 4P-PHARMA SAS ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 4.1 4P-Pharma SAS Business Profile
- 4.2 4P-Pharma SAS Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer

- 4.3.3 Route of Administration
- 4.3.4 Orphan Drug/Fast Track/Special Designation
- 4.3.5 Geography
- 4.3.6 Type of Molecular Entity
- 4.3.7 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 AEVI GENOMIC MEDICINE INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 5.1 Aevi Genomic Medicine Inc Business Profile
- 5.2 Aevi Genomic Medicine Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 AMARANTUS BIOSCIENCE HOLDINGS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 6.1 Amaranthus Bioscience Holdings Inc Business Profile
- 6.2 Amaranthus Bioscience Holdings Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration

- 6.3.4 Orphan Drug/Fast Track/Special Designation
- 6.3.5 Geography
- 6.3.6 Type of Molecular Entity
- 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 APET HOLDING BV ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 7.1 APeT Holding BV Business Profile
- 7.2 APeT Holding BV Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 ARCTURUS THERAPEUTICS LTD ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 8.1 Arcturus Therapeutics Ltd Business Profile
- 8.2 Arcturus Therapeutics Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography

- 8.3.6 Type of Molecular Entity
- 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 ASTRAZENECA ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 9.1 AstraZeneca Business Profile
- 9.2 AstraZeneca Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 9.3 Drug Snapshot
 - 9.3.1 Originator
 - 9.3.2 Collaborator/Co-Developer
 - 9.3.3 Route of Administration
 - 9.3.4 Orphan Drug/Fast Track/Special Designation
 - 9.3.5 Geography
 - 9.3.6 Type of Molecular Entity
 - 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 AVEKSHAN LLC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 10.1 Avekshan LLC Business Profile
- 10.2 Avekshan LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview

- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 BCWORLD PHARM CO LTD ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 11.1 BCWorld Pharm Co Ltd Business Profile
- 11.2 BCWorld Pharm Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography
 - 11.3.6 Type of Molecular Entity
 - 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 BIOHEALTHONOMICS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 12.1 BioHealthonomics Inc Business Profile
- 12.2 BioHealthonomics Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

13 BIONOMICS LTD ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

13.1 Bionomics Ltd Business Profile

13.2 Bionomics Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details

13.3 Drug Snapshot

13.3.1 Originator

13.3.2 Collaborator/Co-Developer

13.3.3 Route of Administration

13.3.4 Orphan Drug/Fast Track/Special Designation

13.3.5 Geography

13.3.6 Type of Molecular Entity

13.3.7 Current Status

13.4 Drug Overview

13.5 Drug Mechanism of Action

13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14 CANNABIS SCIENCE INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

14.1 Cannabis Science Inc Business Profile

14.2 Cannabis Science Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details

14.3 Drug Snapshot

14.3.1 Originator

14.3.2 Collaborator/Co-Developer

14.3.3 Route of Administration

14.3.4 Orphan Drug/Fast Track/Special Designation

14.3.5 Geography

14.3.6 Type of Molecular Entity

14.3.7 Current Status

14.4 Drug Overview

14.5 Drug Mechanism of Action

14.6 Clinical/Pre-clinical Trial Details

14.7 Latest Drug Developments

15 CENNERV PHARMA (S) PTE LTD ATTENTION DEFICIT HYPERACTIVITY

DISORDER (ADHD) PIPELINE DETAILS

- 15.1 Cennerv Pharma (S) Pte Ltd Business Profile
- 15.2 Cennerv Pharma (S) Pte Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 CINGULATE THERAPEUTICS ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 16.1 Cingulate Therapeutics Business Profile
- 16.2 Cingulate Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 CINGULATE THERAPEUTICS LLC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 17.1 Cingulate Therapeutics LLC Business Profile
- 17.2 Cingulate Therapeutics LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation
 - 17.3.5 Geography
 - 17.3.6 Type of Molecular Entity
 - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 COLLEGIUM PHARMACEUTICAL INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 18.1 Collegium Pharmaceutical Inc Business Profile
- 18.2 Collegium Pharmaceutical Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer
 - 18.3.3 Route of Administration
 - 18.3.4 Orphan Drug/Fast Track/Special Designation
 - 18.3.5 Geography
 - 18.3.6 Type of Molecular Entity
 - 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 CUREMARK LLC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 19.1 Curemark LLC Business Profile
- 19.2 Curemark LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 DURECT CORP ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 20.1 DURECT Corp Business Profile
- 20.2 DURECT Corp Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 ENCEPHEAL THERAPEUTICS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 21.1 EncepHeal Therapeutics Inc Business Profile
- 21.2 EncepHeal Therapeutics Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details

- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 ENSYSCE BIOSCIENCES INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 22.1 Ensysce Biosciences Inc Business Profile
- 22.2 Ensysce Biosciences Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity
 - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 HIGHLAND THERAPEUTICS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 23.1 Highland Therapeutics Inc Business Profile
- 23.2 Highland Therapeutics Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 23.3 Drug Snapshot

- 23.3.1 Originator
- 23.3.2 Collaborator/Co-Developer
- 23.3.3 Route of Administration
- 23.3.4 Orphan Drug/Fast Track/Special Designation
- 23.3.5 Geography
- 23.3.6 Type of Molecular Entity
- 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 INVENT PHARMACEUTICALS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 24.1 INVENT Pharmaceuticals Inc Business Profile
- 24.2 INVENT Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25 KEMPHARM INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 25.1 KemPharm Inc Business Profile
- 25.2 KemPharm Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 25.3 Drug Snapshot
 - 25.3.1 Originator
 - 25.3.2 Collaborator/Co-Developer

- 25.3.3 Route of Administration
- 25.3.4 Orphan Drug/Fast Track/Special Designation
- 25.3.5 Geography
- 25.3.6 Type of Molecular Entity
- 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26 LEON-NANODRUGS GMBH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 26.1 leon-nanodrugs GmbH Business Profile
- 26.2 leon-nanodrugs GmbH Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 26.3 Drug Snapshot
 - 26.3.1 Originator
 - 26.3.2 Collaborator/Co-Developer
 - 26.3.3 Route of Administration
 - 26.3.4 Orphan Drug/Fast Track/Special Designation
 - 26.3.5 Geography
 - 26.3.6 Type of Molecular Entity
 - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27 LIMOXIFEN BV ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 27.1 Limoxifen BV Business Profile
- 27.2 Limoxifen BV Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 27.3 Drug Snapshot
 - 27.3.1 Originator
 - 27.3.2 Collaborator/Co-Developer
 - 27.3.3 Route of Administration
 - 27.3.4 Orphan Drug/Fast Track/Special Designation

- 27.3.5 Geography
- 27.3.6 Type of Molecular Entity
- 27.3.7 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

28 NLS PHARMA GROUP ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 28.1 NLS Pharma Group Business Profile
- 28.2 NLS Pharma Group Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 28.3 Drug Snapshot
 - 28.3.1 Originator
 - 28.3.2 Collaborator/Co-Developer
 - 28.3.3 Route of Administration
 - 28.3.4 Orphan Drug/Fast Track/Special Designation
 - 28.3.5 Geography
 - 28.3.6 Type of Molecular Entity
 - 28.3.7 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

29 NOVARTIS AG ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 29.1 Novartis AG Business Profile
- 29.2 Novartis AG Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 29.3 Drug Snapshot
 - 29.3.1 Originator
 - 29.3.2 Collaborator/Co-Developer
 - 29.3.3 Route of Administration
 - 29.3.4 Orphan Drug/Fast Track/Special Designation
 - 29.3.5 Geography
 - 29.3.6 Type of Molecular Entity
 - 29.3.7 Current Status

- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action
- 29.6 Clinical/Pre-clinical Trial Details
- 29.7 Latest Drug Developments

30 NOVEN PHARMACEUTICALS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 30.1 Noven Pharmaceuticals Inc Business Profile
- 30.2 Noven Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 30.3 Drug Snapshot
 - 30.3.1 Originator
 - 30.3.2 Collaborator/Co-Developer
 - 30.3.3 Route of Administration
 - 30.3.4 Orphan Drug/Fast Track/Special Designation
 - 30.3.5 Geography
 - 30.3.6 Type of Molecular Entity
 - 30.3.7 Current Status
- 30.4 Drug Overview
- 30.5 Drug Mechanism of Action
- 30.6 Clinical/Pre-clinical Trial Details
- 30.7 Latest Drug Developments

31 OTSUKA PHARMACEUTICAL CO LTD ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 31.1 Otsuka Pharmaceutical Co Ltd Business Profile
- 31.2 Otsuka Pharmaceutical Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 31.3 Drug Snapshot
 - 31.3.1 Originator
 - 31.3.2 Collaborator/Co-Developer
 - 31.3.3 Route of Administration
 - 31.3.4 Orphan Drug/Fast Track/Special Designation
 - 31.3.5 Geography
 - 31.3.6 Type of Molecular Entity
 - 31.3.7 Current Status
- 31.4 Drug Overview

- 31.5 Drug Mechanism of Action
- 31.6 Clinical/Pre-clinical Trial Details
- 31.7 Latest Drug Developments

32 P2D INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 32.1 P2D Inc Business Profile
- 32.2 P2D Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 32.3 Drug Snapshot
 - 32.3.1 Originator
 - 32.3.2 Collaborator/Co-Developer
 - 32.3.3 Route of Administration
 - 32.3.4 Orphan Drug/Fast Track/Special Designation
 - 32.3.5 Geography
 - 32.3.6 Type of Molecular Entity
 - 32.3.7 Current Status
- 32.4 Drug Overview
- 32.5 Drug Mechanism of Action
- 32.6 Clinical/Pre-clinical Trial Details
- 32.7 Latest Drug Developments

33 RESPIRERX PHARMACEUTICALS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 33.1 RespireRx Pharmaceuticals Inc Business Profile
- 33.2 RespireRx Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 33.3 Drug Snapshot
 - 33.3.1 Originator
 - 33.3.2 Collaborator/Co-Developer
 - 33.3.3 Route of Administration
 - 33.3.4 Orphan Drug/Fast Track/Special Designation
 - 33.3.5 Geography
 - 33.3.6 Type of Molecular Entity
 - 33.3.7 Current Status
- 33.4 Drug Overview
- 33.5 Drug Mechanism of Action
- 33.6 Clinical/Pre-clinical Trial Details

33.7 Latest Drug Developments

34 REVIVA PHARMACEUTICALS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

34.1 Reviva Pharmaceuticals Inc Business Profile

34.2 Reviva Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details

34.3 Drug Snapshot

34.3.1 Originator

34.3.2 Collaborator/Co-Developer

34.3.3 Route of Administration

34.3.4 Orphan Drug/Fast Track/Special Designation

34.3.5 Geography

34.3.6 Type of Molecular Entity

34.3.7 Current Status

34.4 Drug Overview

34.5 Drug Mechanism of Action

34.6 Clinical/Pre-clinical Trial Details

34.7 Latest Drug Developments

35 SEROPEUTICS LLC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

35.1 Seropeutics LLC Business Profile

35.2 Seropeutics LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Details

35.3 Drug Snapshot

35.3.1 Originator

35.3.2 Collaborator/Co-Developer

35.3.3 Route of Administration

35.3.4 Orphan Drug/Fast Track/Special Designation

35.3.5 Geography

35.3.6 Type of Molecular Entity

35.3.7 Current Status

35.4 Drug Overview

35.5 Drug Mechanism of Action

35.6 Clinical/Pre-clinical Trial Details

35.7 Latest Drug Developments

36 SHENOX PHARMACEUTICALS ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 36.1 Shenox Pharmaceuticals Business Profile
- 36.2 Shenox Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 36.3 Drug Snapshot
 - 36.3.1 Originator
 - 36.3.2 Collaborator/Co-Developer
 - 36.3.3 Route of Administration
 - 36.3.4 Orphan Drug/Fast Track/Special Designation
 - 36.3.5 Geography
 - 36.3.6 Type of Molecular Entity
 - 36.3.7 Current Status
- 36.4 Drug Overview
- 36.5 Drug Mechanism of Action
- 36.6 Clinical/Pre-clinical Trial Details
- 36.7 Latest Drug Developments

37 SHIONOGI & CO LTD ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 37.1 Shionogi & Co Ltd Business Profile
- 37.2 Shionogi & Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 37.3 Drug Snapshot
 - 37.3.1 Originator
 - 37.3.2 Collaborator/Co-Developer
 - 37.3.3 Route of Administration
 - 37.3.4 Orphan Drug/Fast Track/Special Designation
 - 37.3.5 Geography
 - 37.3.6 Type of Molecular Entity
 - 37.3.7 Current Status
- 37.4 Drug Overview
- 37.5 Drug Mechanism of Action
- 37.6 Clinical/Pre-clinical Trial Details
- 37.7 Latest Drug Developments

38 SHIRE PHARMACEUTICALS LTD ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 38.1 Shire Pharmaceuticals Ltd Business Profile
- 38.2 Shire Pharmaceuticals Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 38.3 Drug Snapshot
 - 38.3.1 Originator
 - 38.3.2 Collaborator/Co-Developer
 - 38.3.3 Route of Administration
 - 38.3.4 Orphan Drug/Fast Track/Special Designation
 - 38.3.5 Geography
 - 38.3.6 Type of Molecular Entity
 - 38.3.7 Current Status
- 38.4 Drug Overview
- 38.5 Drug Mechanism of Action
- 38.6 Clinical/Pre-clinical Trial Details
- 38.7 Latest Drug Developments

39 SK BIOPHARMACEUTICALS CO LTD ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 39.1 SK Biopharmaceuticals Co Ltd Business Profile
- 39.2 SK Biopharmaceuticals Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details
- 39.3 Drug Snapshot
 - 39.3.1 Originator
 - 39.3.2 Collaborator/Co-Developer
 - 39.3.3 Route of Administration
 - 39.3.4 Orphan Drug/Fast Track/Special Designation
 - 39.3.5 Geography
 - 39.3.6 Type of Molecular Entity
 - 39.3.7 Current Status
- 39.4 Drug Overview
- 39.5 Drug Mechanism of Action
- 39.6 Clinical/Pre-clinical Trial Details
- 39.7 Latest Drug Developments

40 SUNOVION PHARMACEUTICALS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 40.1 Sunovion Pharmaceuticals Inc Business Profile
- 40.2 Sunovion Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD)
Drug Details
- 40.3 Drug Snapshot
 - 40.3.1 Originator
 - 40.3.2 Collaborator/Co-Developer
 - 40.3.3 Route of Administration
 - 40.3.4 Orphan Drug/Fast Track/Special Designation
 - 40.3.5 Geography
 - 40.3.6 Type of Molecular Entity
 - 40.3.7 Current Status
- 40.4 Drug Overview
- 40.5 Drug Mechanism of Action
- 40.6 Clinical/Pre-clinical Trial Details
- 40.7 Latest Drug Developments

41 SUPERNUS PHARMACEUTICALS INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 41.1 Supernus Pharmaceuticals Inc Business Profile
- 41.2 Supernus Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD)
Drug Details
- 41.3 Drug Snapshot
 - 41.3.1 Originator
 - 41.3.2 Collaborator/Co-Developer
 - 41.3.3 Route of Administration
 - 41.3.4 Orphan Drug/Fast Track/Special Designation
 - 41.3.5 Geography
 - 41.3.6 Type of Molecular Entity
 - 41.3.7 Current Status
- 41.4 Drug Overview
- 41.5 Drug Mechanism of Action
- 41.6 Clinical/Pre-clinical Trial Details
- 41.7 Latest Drug Developments

42 TAHO PHARMACEUTICALS LTD ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

- 42.1 Taho Pharmaceuticals Ltd Business Profile

42.2 Taho Pharmaceuticals Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details

42.3 Drug Snapshot

42.3.1 Originator

42.3.2 Collaborator/Co-Developer

42.3.3 Route of Administration

42.3.4 Orphan Drug/Fast Track/Special Designation

42.3.5 Geography

42.3.6 Type of Molecular Entity

42.3.7 Current Status

42.4 Drug Overview

42.5 Drug Mechanism of Action

42.6 Clinical/Pre-clinical Trial Details

42.7 Latest Drug Developments

43 TAISHO PHARMACEUTICAL HOLDINGS CO LTD ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

43.1 Taisho Pharmaceutical Holdings Co Ltd Business Profile

43.2 Taisho Pharmaceutical Holdings Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Details

43.3 Drug Snapshot

43.3.1 Originator

43.3.2 Collaborator/Co-Developer

43.3.3 Route of Administration

43.3.4 Orphan Drug/Fast Track/Special Designation

43.3.5 Geography

43.3.6 Type of Molecular Entity

43.3.7 Current Status

43.4 Drug Overview

43.5 Drug Mechanism of Action

43.6 Clinical/Pre-clinical Trial Details

43.7 Latest Drug Developments

44 TRIS PHARMA INC ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DETAILS

44.1 Tris Pharma Inc Business Profile

44.2 Tris Pharma Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Details

44.3 Drug Snapshot

44.3.1 Originator

44.3.2 Collaborator/Co-Developer

44.3.3 Route of Administration

44.3.4 Orphan Drug/Fast Track/Special Designation

44.3.5 Geography

44.3.6 Type of Molecular Entity

44.3.7 Current Status

44.4 Drug Overview

44.5 Drug Mechanism of Action

44.6 Clinical/Pre-clinical Trial Details

44.7 Latest Drug Developments

45. LATEST ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) DRUG PIPELINE DEVELOPMENTS, 2019

46. APPENDIX

46.1 About Us

46.2 Sources and Methodology

46.3 Contact Information

I would like to order

Product name: 2019 Future of Attention Deficit Hyperactivity Disorder (ADHD) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/237EE48940EEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/237EE48940EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970